Metaxantrone is good for treatment of multiple sclerosis but should be use by another corticoostroids.
Mitoxantrone is an anthracenedione chemotherapeutic agent that was studied as treatment for Multiple Sclerosis and is FDA approved for that indication, including relapsing forms of MS and secondary progressive MS. Despite the documented efficacy, the seriousness and rate at which two potential side effects (cardiotoxicity and AML) occur, made the product fall in disfavor and is not commonly used any longer.
Mitoxantrone has a limited role in the treatment of MS in the current scenario. Apart from the short period that it can be administered, treatment induced leukemia ( even as far as > 5 yrs after treatment) and cardiac toxicity are reasons for not preferring this drug. However in aggressive MS that has not responded to first line therapy ( for eg. while compliant on Betainterferon , patient develops > 2 severe clinical relapses /yr or has increasing T2 W lesion load or > 2 GAD enhancing lesions) , then there is a limited role for Mitoxantrone to INDUCE Remission , to be followed later by a less toxic first line drug.
- Badges
- Science method